JSP Pharmaceutical Manufacturing (Thailand) Public Valuation
Is JSP-F undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of JSP-F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate JSP-F's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate JSP-F's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for JSP-F?
Other financial metrics that can be useful for relative valuation.
What is JSP-F's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ฿1.12b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 2.3x |
Enterprise Value/EBITDA | 36.4x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does JSP-F's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 1.9x | ||
BLC Bangkok Lab And Cosmetic | 1.9x | n/a | ฿2.8b |
MEGA Mega Lifesciences | 2.1x | 4.6% | ฿32.7b |
A080720 Union Korea Pharm | 0.6x | n/a | ₩40.8b |
PAR Par Drugs and Chemicals | 2.9x | n/a | ₹2.8b |
JSP-F JSP Pharmaceutical Manufacturing (Thailand) Public | 1.7x | n/a | ฿1.1b |
Price-To-Sales vs Peers: JSP-F is good value based on its Price-To-Sales Ratio (1.7x) compared to the peer average (1.9x).
Price to Earnings Ratio vs Industry
How does JSP-F's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?
Price-To-Sales vs Industry: JSP-F is good value based on its Price-To-Sales Ratio (1.7x) compared to the Asian Pharmaceuticals industry average (2.4x).
Price to Sales Ratio vs Fair Ratio
What is JSP-F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 1.8x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate JSP-F's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.